{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:26:30Z","timestamp":1772720790211,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11547-019-01093-x","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:02:53Z","timestamp":1570100573000},"page":"98-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study"],"prefix":"10.1007","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-8813","authenticated-orcid":false,"given":"Antonio","family":"Orlacchio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Chegai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Roma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Merolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Francioso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"C-M Lo","year":"2002","unstructured":"Lo C-M, Ngan H, Tso W-K et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164\u20131171","journal-title":"Hepatology"},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734\u20131739","journal-title":"Lancet"},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jhep.2010.01.031","volume":"53","author":"E Tsochatzis","year":"2010","unstructured":"Tsochatzis E, Meyer T, Marelli L, Burroughs AK (2010) Which transarterial therapy is best for hepatocellular carcinoma?\u2014the evidence to date. J Hepatol 53:588","journal-title":"J Hepatol"},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2217\/hep.15.32","volume":"2","author":"F Chegai","year":"2015","unstructured":"Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L (2015) Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepatic Oncol 2:399\u2013408","journal-title":"Hepatic Oncol"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00270-016-1340-3","volume":"39","author":"G Mauri","year":"2016","unstructured":"Mauri G, Varano GM, Orsi F (2016) TAE for HCC: when the old way is better than the new ones!!! Cardiovasc Interv Radiol 39:799\u2013800","journal-title":"Cardiovasc Interv Radiol"},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932\u2013936","journal-title":"Nature"},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0033-1333648","volume":"30","author":"R Lencioni","year":"2013","unstructured":"Lencioni R, Petruzzi P, Crocetti L (2013) Chemoembolization of hepatocellular carcinoma. Semin Interv Radiol 30:3\u201311","journal-title":"Semin Interv Radiol"},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jvir.2009.12.390","volume":"21","author":"JP Erinjeri","year":"2010","unstructured":"Erinjeri JP, Salhab HM, Covey AM, Getrajdman GI, Brown KT (2010) Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol 21:522\u2013526","journal-title":"J Vasc Interv Radiol"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.14218\/JCTH.2016.00058","volume":"4","author":"A Schicho","year":"2016","unstructured":"Schicho A, Hellerbrand C, Kr\u00fcger K et al (2016) Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels. J Clin Transl Hepatol 4:288\u2013292","journal-title":"J Clin Transl Hepatol"},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00270-014-0966-2","volume":"38","author":"CC Pieper","year":"2015","unstructured":"Pieper CC, Meyer C, Vollmar B, Hauenstein K, Schild HH, Wilhelm KE (2015) Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCept(\u00ae)S) in a swine model. Cardiovasc Interv Radiol 38:435\u2013441","journal-title":"Cardiovasc Interv Radiol"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.COC.0000018174.53573.67","volume":"26","author":"J Furuse","year":"2003","unstructured":"Furuse J, Ishii H, Satake M et al (2003) Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol 26:159\u2013164","journal-title":"Am J Clin Oncol"},{"key":"1093_CR12","first-page":"259","volume":"6","author":"TD Kirchhoff","year":"2007","unstructured":"Kirchhoff TD, Bleck JS, Dettmer A et al (2007) Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int 6:259\u2013266","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2174\/1573405613666170616123657","volume":"14","author":"A Orlacchio","year":"2018","unstructured":"Orlacchio A, Chegai F, Francioso S et al (2018) Repeated transarterial chemoembolization with degradable starch microspheres (DSMs-TACE) of unresectable hepatocellular carcinoma: a prospective pilot study. Curr Med Imaging Rev 14:637\u2013645","journal-title":"Curr Med Imaging Rev"},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"052","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:052\u2013060","journal-title":"Semin Liver Dis"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1586\/egh.11.105","volume":"6","author":"RG Gish","year":"2012","unstructured":"Gish RG, Lencioni R, Di Bisceglie AM, Raoul J-L, Mazzaferro V (2012) Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 6:173\u2013185","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jvir.2011.11.029","volume":"23","author":"DB Brown","year":"2012","unstructured":"Brown DB, Nikolic B, Covey AM et al (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23:287\u2013294","journal-title":"J Vasc Interv Radiol"},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer","year":"2012","unstructured":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908\u2013943","journal-title":"J Hepatol"},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/liv.13888","volume":"38","author":"A Sangiovanni","year":"2018","unstructured":"Sangiovanni A, Triolo M, Iavarone M et al (2018) Multimodality treatment of hepatocellular carcinoma: how field practice complies with international recommendations. Liver Int 38:1624\u20131634","journal-title":"Liver Int"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jvir.2013.10.007","volume":"25","author":"C Niessen","year":"2014","unstructured":"Niessen C, Unterpaintner E, Goessmann H et al (2014) Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 25:240\u2013247","journal-title":"J Vasc Interv Radiol"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12885-018-4099-x","volume":"18","author":"T Gruber-Rouh","year":"2018","unstructured":"Gruber-Rouh T, Schmitt C, Naguib NNN et al (2018) Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. BMC Cancer 18:188","journal-title":"BMC Cancer"},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MEG.0b013e328346d505","volume":"23","author":"MJ Song","year":"2011","unstructured":"Song MJ, Park C-H, Kim JD et al (2011) Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 23:521\u2013527","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"72613","DOI":"10.18632\/oncotarget.19997","volume":"8","author":"A Schicho","year":"2017","unstructured":"Schicho A, Pereira PL, Haimerl M et al (2017) Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget 8:72613\u201372620","journal-title":"Oncotarget"},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1148\/radiol.12112264","volume":"265","author":"C Georgiades","year":"2012","unstructured":"Georgiades C, Geschwind J-F, Harrison N et al (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265:115\u2013123","journal-title":"Radiology"},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","volume":"34","author":"KT Brown","year":"2016","unstructured":"Brown KT, Do RK, Gonen M et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34:2046\u20132053","journal-title":"J Clin Oncol"},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejso.2005.11.003","volume":"32","author":"TD Kirchhoff","year":"2006","unstructured":"Kirchhoff TD, Rudolph KL, Layer G et al (2006) Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol 32:201\u2013207","journal-title":"Eur J Surg Oncol"},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jhep.2015.01.022","volume":"62","author":"BK Kim","year":"2015","unstructured":"Kim BK, Kim SU, Kim KA et al (2015) Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol 62:1304\u20131310","journal-title":"J Hepatol"},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jvir.2012.10.021","volume":"24","author":"SP Kalva","year":"2013","unstructured":"Kalva SP, Pectasides M, Yeddula K, Ganguli S, Blaszkowsky LS, Zhu AX (2013) Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. J Vasc Interv Radiol 24:257\u2013265","journal-title":"J Vasc Interv Radiol"},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1148\/radiol.11110282","volume":"262","author":"JH Shim","year":"2012","unstructured":"Shim JH, Lee HC, Kim S-O et al (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262:708\u2013718","journal-title":"Radiology"},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.dld.2013.03.004","volume":"45","author":"R Sacco","year":"2013","unstructured":"Sacco R, Faggioni L, Bargellini I et al (2013) Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. Dig Liver Dis 45:776\u2013781","journal-title":"Dig Liver Dis"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-019-01093-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11547-019-01093-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-019-01093-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T23:48:21Z","timestamp":1601596101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11547-019-01093-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s11547-019-01093-x","relation":{},"ISSN":["0033-8362","1826-6983"],"issn-type":[{"value":"0033-8362","type":"print"},{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"assertion":[{"value":"8 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared no potential conflicts of interests associated with this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}